SCHEMBL3531252

SCHEMBL3531252

N#Cc1ccc(-c2cc(N)ccc2F)s1.Nc1ccc(F)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
INPPL1 O15357 2/20 0.38
BACE1 P56817 1/20 0.34
MCHR1 Q99705 1/20 0.33
KDM1A O60341 1/20 0.33
CYP3A4 P08684 3/20 0.33
TSHR P16473 1/20 0.33
S1PR1 P21453 1/20 0.32
S1PR3 Q99500 1/20 0.32
EGFR P00533 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31
PGR P06401 2/20 0.30
NR3C1 P04150 1/20 0.30
AR P10275 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3982568 0.92 BACE1 (0.38) INPPL1BACE1KDM1AS1PR1S1PR3
SCHEMBL3522964 0.74 ERN1 (0.43) MCHR1KDM4EMAPTHPGD
SCHEMBL29418051 0.72
SCHEMBL17356182 0.72
SCHEMBL9602 0.72
Hydrochloric Acid SCHEMBL6186117 0.70 CYP3A4 (0.56) CYP3A4TSHREGFRKDM4EMEN1
Iodide SCHEMBL31415635 0.70 CYP3A4 (0.56) CYP3A4TSHREGFRMEN1MAPT
Fluoride SCHEMBL27766501 0.70 CYP3A4 (0.56) CYP3A4TSHREGFRMEN1MAPT
Ammonia Solution, Strong SCHEMBL27721437 0.70 CYP3A4 (0.56) CYP3A4TSHREGFRMEN1MAPT
SCHEMBL27781708 0.68 ALDH1A1 (0.40) BACE1MCHR1S1PR1S1PR3EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759366-B2 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2010-07-20 US disclosed
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2009-08-27 US disclosed
CN-101501005-A Arylaminoaryl-alkyl-substituted imidazolidine-2, 4-diones, processes for their preparation, medicaments comprising these compounds and their use SANOFI AVENTIS (FR) 2009-08-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use GPR119, GIPR, LIPC INPPL1 868/4885BACE1 3742/4885MCHR1 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.